European Psychiatry - Volume 41 - April 2017

820 / 916

S816 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S772–S846
tine levels were normalized. Overall, 72% described a clinical
improvement, especially in terms of sexual dysfunction.
Conclusions Several studies have described an improvement of
drug-induced hyperprolactinemia after switching to or adding oral
aripiprazole. In our study, we observed that levels of prolactine
were normalized in 85% of patients with a clinical improve-
ment in almost all of cases. These findings suggest that switching
to LAI aripiprazole may be an effective alternative for manag-
ing antipsychotic-induced hyperprolactinemia due to its partial
agonism in D2 brain receptors, especially in tuberoinfundibular
pathway.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1256
The side effects of risperidone depot
in patients with psychotic disorders
T. Jupe ∗, F. Elezi , B. Zenelaj , E. Myslimi
1 UHC Mother Tereza, Psychiatry, Tirane, Albania
2 UHC Mother Thereza, Psychiatry, Tirane, Albania
∗ Corresponding author.
Background and aim A long-acting form of risperidone is now
broadly available for the treatment of schizophrenia and closely
related psychiatric conditions. It combines the advantage of previ-
ously available depot formulations for first-generation drugs with
the favorable characteristics of the modern “atypical” antipsy-
chotics, namely higher efficacy in the treatment of the negative
symptoms of schizophrenia and reduced motor disturbances
Methods During this study, we observed side effects that appear
in patients that are treated with risperidone depot. Patients were
observed for a period of 3 months (October–December 2015) and
the side effects were evaluated with Glasgow Antipsychotic Side-
effect Scale (GASS). The data obtained were analyzed with SPSS,
trying to prove the impact of variables such as: gender, age, diag-
nosis, dose and duration of treatment on the occurrence of side
effects.
Results Through statistical processing, we reached the conclu-
sion that there is a statistically significant correlation between
duration of treatment and side effects (P value was 0.0001).
Between two variables has a strong positive correlation (Kendall
value was 0.766). Has a statistically significant correlation between
the drug dose and side effects ( P value was 0.026). Between
two variables has a moderate positive correlation (Kendall value
was 0.504). No statistically significant correlation between these
variables: gender-side effects, diagnose-side effects and age-side
effects.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Reference
[1] Emsley R, Medori R, Koen L, et al. Long-acting injectable risperi-
done in the treatment of subjects with recent–onset psychosis:
a preliminary study. J Clin Psychopharmacol 28:210-213.
EV1257
Mortality in people with psychotic
disorders in Finland:
A population-based 13-year follow-up
study
J. Keinänen ∗, O. Mantere , N. Markkula , K. Partti , J. Perälä ,
S.I. Saarni , T. Härkänen , J. Suvisaari
1 National Institute for Health and Welfare, Department of Mental
Health and Substance Abuse Services, Helsinki, Finland
2 McGill University, Department of Psychiatry, Montreal, Canada
3 National Institute for Health and Welfare, Department of Health-
Functional Capacity and Welfare, Helsinki, Finland
∗ Corresponding author.
Introduction People with psychotic disorders have increased
mortality compared to the general population. The mortality is
mostly due to natural causes and it is disproportionately high com-
pared to the somatic morbidity of people with psychotic disorders.
Objectives We aimed to find predictors of mortality in psychotic
disorders and to evaluate the extent to which sociodemographic
and health-related factors explain the excess mortality.
Methods In a nationally representative sample of Finns aged
30–70 years (n = 5642), psychotic disorders were diagnosed in
2000–2001. Information on mortality and causes of death was
obtained of those who died by the end of year 2013. Cox pro-
portional hazards models were used to investigate the mortality
risk.
Results Adjusting for age and sex, diagnosis of nonaffective
psychotic disorder (NAP) (n = 106) was statistically significantly
associated with all-cause mortality (HR 2.99, 95% CI 2.03–4.41) and
natural-cause mortality (HR 2.81, 95% CI 1.85–4.28). After adjus-
ting for sociodemographic factors, health status, inflammation and
smoking, the HR dropped to 2.11 (95% CI 1.10–4.05) for all-cause
and to 1.98 (95% CI 0.94–4.16) for natural-cause mortality. Within
the NAP group, antipsychotic use at baseline was associated with
reduced HR for natural-causemortality (HR 0.25, 95% CI 0.07–0.96),
and smoking with increased HR (HR 3.54, 95% CI 1.07–11.69).
Conclusions The elevated mortality risk associated with NAP
is only partly explained by socioeconomic factors, lifestyle, car-
diometabolic comorbidities and inflammation. Smoking cessation
should be prioritized in treatment of psychotic disorders. More
research is needed on the quality of treatment of somatic conditions
in people with psychotic disorders.
Disclosure of interest Jaakko Keinänen owns shares in pharma-
ceutical company Orion.
EV1258
Validation of the Czech version of the
community assessment of psychic
experiences (CAPE)
B. Keˇrková ∗, Z. Martínková
1 Charles University in Prague and General University Hospital in
Prague, Department of Psychiatry, First Faculty of Medicine, Prague,
Czech Republic
2 Charles University in Prague, Film Studies Department, Faculty of
Philosophy and Arts, Prague, Czech Republic
∗ Corresponding author.
Introduction In the Czech Republic, research of the schizophrenia
spectrum suffers from a lack of standardized measuring instru-
ments. The community assessment of psychic experiences (CAPE)
has been used internationally to quantify positive, negative and
affective symptoms associated with the spectrum and to screen
individuals who may be in risk of developing a spectrum disorder.
Aims and objectives This study aimed to develop a Czech ver-
sion of the CAPE and to examine its psychometric properties in
a nonclinical population.
Methods An author with an expertise in the field and a subject-
naïve author translated the CAPE into the Czech language. After a
professional back-translation, the instrument’s most suitable ver-
sion was agreed upon. Lie-scale items were added to allow for an
online circulation. The CAPE was administered to a large sample of
participants alongside the Beck depression inventory (BDI-II).
Results Internal consistency was assessed using the Cronbach’s
alpha. Internal structure was evaluated using confirmatory factor
analysis and compared to the structure of the original. Criterion
validity was examined through correlation analyses of the BDI-II
scores and the total and subtotal CAPE scores.